Under construction – not a live service
Sign in
Taking people in SwitzerlandNo phase

Long-term study of people with recent HIV-1 infection in Zurich

Observes people newly infected with HIV-1 to learn how early infection progresses.

Plain-language title generated from the registry record
Registry title: Characterization of Acute and Recent HIV-1 Infections in Zurich.

Key facts

Where
Zurich, SwitzerlandSee the site

Where in Switzerland

  • University of ZurichZurich, SwitzerlandTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University of Zurich
Trial code
NCT00537966
Record updated
17 December 2024
Original description
Aim of the study: To study and to describe factors which could influence the course of primary HIV infection (PHI) and factors that in turn could be influenced through PHI.Read full original descriptionShow less

Characterization of Acute and Recent HIV-1 Infections in Zurich. a Long-term Observational Study: the Zurich Primary HIV Infection Study.

Aim of the study: To study and to describe factors which could influence the course of primary HIV infection (PHI) and factors that in turn could be influenced through PHI.

In summary, this study will provide comprehensive knowledge on early HIV-infection with regard to epidemiology, impact of early-cART on the course of disease and forms the base for a variety of translational research projects addressing early key pathogenesis events between virus and host, relevant for the course of disease, for transmission, for development of vaccines and new treatment strategies.

Inclusion: acute HIV-1 infection, defined as:; negative or evolving immunoblot in the presence of positive p24 Ag and/or detectable plasma HIV-1 RNA and/or; documented HIV seroconversion within 90 dayswith or with-out symptoms and/or clinical signs of PHI (e.g. acute retro-viral syndrome); recent HIV-1 infection, defined as:; documented seroconversion of more than 90 days but within 180 days and/or; evolving immunoblot after unambiguous transmission risk (e.g. iv drug use, sexual contact) within 180 days and/or; documented HIV infection and unambiguous transmission risk (iv drug use, sexual contact) within 180 days and/or; documented HIV infection and possible transmission risk (iv drug use, sexual contact) within the last 180 days after infection AND < 0.5% fraction of ambiguous nucleotides.

Exclusion: Documented HIV infection, however, established diagnosis more than 180 days after presumed date of infection.

ClinicalTrials.gov NCT00537966